Antibody biomarkers in CNS demyelinating diseases - a long and winding road

European Journal of Neurology

Volumn 22, Issue 8, 2015, Pages 1162-1168

  Berger, T ^a   Reindl, M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

ADEM; AQP4; JCV; MOG; MS; NAB; NMOSD; OCB

Indexed keywords

ANTIBODY; AQUAPORIN 4 ANTIBODY; BIOLOGICAL MARKER; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL KIR4.1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; UNCLASSIFIED DRUG;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; DEMYELINATING AUTOIMMUNE DISEASES, CNS; IMMUNOLOGY;

ANTIBODIES; BIOMARKERS; DEMYELINATING AUTOIMMUNE DISEASES, CNS; HUMANS;

EID: 84935704551     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12759     Document Type: Review

References (68)

1. Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948; 4: 653-662.
2. Deisenhammer F, Bartos A, Egg R, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006; 13: 913-922.
3. Deisenhammer F, Egg R, Giovannoni G, et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol 2009; 16: 760-770.
4. Bornstein MB, Appel SH. The application of tissue culture to the study of experimental 'allergic' encephalomyelitis. 1. Patterns of demyelination. J Neuropathol Exp Neurol 1961; 20: 141-147.
5. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012; 8: 613-623.
6. Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006; 180: 50-62.
7. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological disease: a comparative study. Brain 1999; 122: 2047-2056.
8. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274.
9. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement mediated demyelination. Ann Neurol 1998; 43: 465-471.
10. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
11. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
12. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
13. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
14. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004; 251 (Suppl. 2): II4-II9.
15. Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force. Eur J Neurol 2005; 12: 817-827.
16. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
17. Waters P, Reindl M, Schanda K, et al. Assessment of aquaporin-4 antibody assays in European diagnostic centres. J Neuroimmunol 2014; 275: 15.
18. Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol 2015; doi: 10.1111/ene.12679 [Epub ahead of print].
19. Mader S, Lutterotti A, Kuenz B, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184-198.
20. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. JAMA Neurol 2012; 69: 752-756.
21. Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19: 1052-1059.
22. Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013; 19: 941-946.
23. Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013; 191: 3594-3604.
24. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-461.
25. Hoftberger R, Selpuveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2014; pii: 1352458514555785 [Epub ahead of print].
26. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283.
27. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 11: 474-481.
28. Hacohen Y, Absoud M, Woodhall M, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry 2014; 85: 456-461.
29. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014; 1: e40.
30. Martinez-Hernandez E, Sepulveda M, Rostasy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015; 72: 187-193.
31. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367: 115-123.
32. Kraus V, Srivastava R, Kalluri SR, et al. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology 2014; 82: 470-473.
33. Brill L, Goldberg L, Karni A, et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult Scler 2015; 21: 572-579.
34. Nerrant E, Salsac C, Charif M, et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 2014; 20: 1699-1703.
35. Brickshawana A, Hinson SR, Romero MF, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2014; 13: 795-806.
36. Brück W, Neubert K, Berger T, Weber JR. Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination - possible markers for an antibody-mediated process. Mult Scler 2001; 7: 173-177.
37. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 2280-2285.
38. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 19057-19062.
39. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13: 211-217.
40. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183: 4067-4076.
41. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138: 247-254.
42. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86: 265-272.
43. Pröbstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77: 580-588.
44. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428.
45. Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015; 2: 295-301.
46. Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015; pii: 1352458514568827 [Epub ahead of print].
47. Dobson R, Ramagopalan S, Davis A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84: 909-914.
48. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-559.
49. Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remission. Arch Neurol 1973; 28: 392-399.
50. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552-556.
51. Berger T, Rubner P, Egg R, et al. Antimyelin antibodies as predictors for clinical definite multiple sclerosis in patients with a first demyelinating event. N Engl J Med 2003; 146: 181-197.
52. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11: 492-494.
53. Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006; 77: 739-742.
54. Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007; 13: 1086-1094.
55. Greeve I, Sellner J, Lauterburg T, et al. Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 2007; 116: 207-210.
56. Kuhle J, Lindberg RLP, Regeniter A, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007; 254: 160-168.
57. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.
58. Pelayo R, Tintore M, Montalban X, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356: 426-428.
59. Robinson WH, Fontoura P, Lee BJ, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003; 21: 1033-1039.
60. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008; 105: 18889-18894.
61. Quintana FJ, Patel B, Yeste A, et al. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology 2014; 83: 2219-1126.
62. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
63. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
64. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated multifocal progressive leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
65. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-750.
66. ™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141-146.
67. Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013; 19: 1533-1538.
68. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802-812.